Bayer Medicines Recall EL(26)A/12: Various Products Recalled at Pharmacy and Wholesaler Level for Impurity

What Has Been Recalled and Why

Bayer Plc has issued a Class 3 recall of all stock of several products listed in the EL(26)A/12 recall notice. The action is precautionary and has been taken following the identification of an impurity above the acceptable specification limit in the affected products. The recall is operating at pharmacy and wholesaler level, meaning that the products must be removed from professional stock but the recall does not extend to contacting individual patients who may have already received the medicines.

The Class 3 designation indicates that the MHRA considers it unlikely that patients who have already used the affected products will suffer adverse health consequences. However, impurity findings above acceptable limits represent a quality non-conformance that requires regulatory action regardless of the severity assessment. The precautionary recall prevents any further dispensing of the affected stock while the investigation proceeds.

Bayer is a major international pharmaceutical manufacturer with a broad product portfolio. The specific products affected are listed in the full EL(26)A/12 recall notice. Pharmacy and wholesale teams holding Bayer products should check the notice carefully and identify whether any of their current stock falls within the recalled items.

Understanding Pharmaceutical Impurity Recalls

Impurity findings are one of the more common triggers for medicines recalls across the global pharmaceutical industry. All licensed medicines have defined acceptable limits for impurities, including process-related impurities from manufacturing, degradation products, and trace residuals from solvents or reagents. These limits are set by regulatory bodies including the MHRA and the European Medicines Agency based on toxicological assessments of the impurity in question.

When a batch or product is found to contain an impurity above these limits, it fails its specification and cannot be distributed. The recall class depends on the nature of the impurity and the estimated level of patient risk. Genotoxic impurities, for example, carry higher risk than process impurities and are more likely to trigger Class 1 or 2 recalls. In this case, the Class 3 classification indicates the impurity finding is considered low risk to patients who have already received the medicine.

For procurement teams, a Bayer recall at pharmacy and wholesaler level is operationally significant because Bayer products are widely stocked. Checking the full product list in the EL(26)A/12 notice and quarantining any affected items promptly ensures compliance with MHRA recall requirements and avoids any further supply of the affected stock.

Steps for Pharmacy and Wholesale Teams

1. Obtain the full EL(26)A/12 recall notice from Bayer Plc to identify which specific products and batch numbers are affected.
2. Check your stock against the recalled product list and batch numbers.
3. Quarantine all affected stock immediately and remove from sale or dispensing.
4. Follow Bayer's return instructions for credit and collection arrangements.
5. Source replacement stock from unaffected batches or alternative licensed suppliers if required.